+1-888-308-5802     
Industry Categories News Contact Us

Pfizer & Astellas Pharma to amend protocols for EMBARK & ARCHES trials

Author : Paroma Bhattacharya | Published Date : 2018-08-24 

One of the world’s largest pharmaceutical companies, Pfizer Inc. and the Japanese drug manufacturer Astellas Pharma Inc. have recently announced that they will be amending the protocols for two late-stage trials designed to test the XTANDI prostate cancer drug with an aim to speed up completion.

Reuters reports that the companies are now planning the end of the ARCHES trial late in 2018 instead of its previously anticipated end date in April 2020. The EMBARK trial is expected to be completed by middle of 2020 instead of the previously set goal of March 2021. Both trials were designed to test the efficacy and safety of XTANDI which is being developed to treat men with hormone-sensitive prostate cancer.

ARCHES is a registrational Phase 3 trial that is meant to evaluate the efficacy of enzalutamide plus androgen deprivation therapy versus androgen deprivation therapy alone in metastatic hormone-sensitive prostate cancer patients. Changes to the protocol will revise the primary endpoint of the trial which is basically radiographic progression-free survival. Revision will also occur in secondary endpoints.

EMBARK is a randomized Phase 3 evaluation of enzalutamide monotherapy, leuprolide alone and enzalutamide plus leuprolide in men with high-risk non-metastatic hormone-sensitive prostate cancer. The amendment of the protocols will mean the revision of the primary endpoint which is metastasis-free survival and the revision of several secondary endpoints which will effectively reduce the target sample size.

Steven Benner, senior VP and global therapeutic area head at Astellas, Oncology Development has been reported to say that the company worked hard to design clinical trials that facilitate innovations to reach people in need. With the amendments in EMBARK and ARCHES, patients with hormone-sensitive prostate cancer would be able to avail XTANDI sooner. Patients with non-metastatic disease will also benefit from the move as there are no approved oral treatment options available for the disease at present.

Incidentally, the U.S. Food and Drug Administration has already approved XTANDI for the treatment of castration-resistant prostate cancer.

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from being a compulsive reader she also loves to cook, paint and travel

She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

Hitachi signs MoU with NSW government to develop Western Sydney

Published Date: 2018-11-16         Author: Paroma Bhattacharya

Hitachi, Ltd., the Japanese conglomerate company recently announced the signing of a Memorandum of Understanding with the New South Wales (NSW) Government of Australia. The MoU is an illustration of Hitachi’s commitment to cooperate with NSW for the development of Western Sydney Aerotropolis a... Read More

BHP buys stake in SolGold copper project in Ecuador for $35 million

Published Date: 2018-09-07         Author: Paroma Bhattacharya

The leading mining company BHP has recently signed a deal with SolGold, the Australian gold and copper mining company to earn a 6.1% stake in the latter. The deal, in which BHP will be paying $35 million for the stakes, will ensure that BHP earns a share in the copper-gold project, Cascabel, Ecuador... Read More

SwRI’s AC2AT-II consortium to focus on engine emissions solutions

Published Date: 2018-09-07         Author: Paroma Bhattacharya

Southwest Research Institute, one of the largest nonprofit R&D organizations in the U.S. recently announced the commencement of the Advanced Combustion Catalyst and Aftertreatment Technologies II, that will be starting from 15 November 2018 with a meeting at the San Antonio headquarters of SwRI.... Read More

© 2018 Fractovia. All Rights Reserved